Pfizer Lyme vaccine shows 74% efficacy but misses primary endpoint
Drugmaker plans FDA approval push despite statistical shortfall in Phase 3 VALOR trial as $1B market opportunity looms
Pfizer shares fell 0.9% on Monday after the pharmaceutical giant and its French partner Valneva reported that their Lyme disease vaccine candidate demonstrated strong efficacy in a Phase 3 trial but failed to meet its primary statistical endpoint due to an unexpectedly low number of infections among study participants.
The vaccine, known as VLA15 and designated PF-07307405 in Pfizer's pipeline, showed 73.2% efficacy in reducing confirmed Lyme disease cases 28 days after the fourth dose, according to results from the VALOR trial, which enrolled more than 6,000 participants aged five and older. In a secondary analysis measuring efficacy one day after the final dose, the protection rate reached 74.8%.
However, the lower bound of the 95% confidence interval in the primary analysis came in at 15.8%, falling short of the required 20% threshold that regulators typically demand for statistical significance. The companies attributed the shortfall to "fewer than anticipated Lyme disease cases accrued over the study period", a statistical challenge that reduced the trial's power to demonstrate efficacy with the precision originally designed.
Despite missing the primary endpoint, Pfizer and Valneva said they plan to move forward with regulatory submissions to the FDA and European Medicines Agency in 2026. The companies cited the "clinically meaningful efficacy" demonstrated in the trial and the fact that a secondary analysis with a slightly different timing met statistical requirements as reasons for their confidence.
The mixed results highlight the challenges pharmaceutical companies face when conducting clinical trials for diseases with variable incidence rates. Lyme disease, caused by bacteria transmitted through tick bites, has expanded its geographic range in recent years due to climate change and other environmental factors, but infection rates can fluctuate significantly year to year depending on weather conditions and tick population dynamics.
"The demonstrated efficacy, combined with a favorable safety profile and the significant unmet medical need, support the continued development of VLA15," Annaliesa Anderson, Pfizer's senior vice president and chief scientific officer for vaccine research and development, said in a statement.
Lyme disease represents a substantial commercial opportunity for Pfizer. The illness affects an estimated 476,000 people annually in the United States and 129,000 in Europe, making it the most common vector-borne disease in the Northern Hemisphere. There is currently no approved Lyme vaccine in the U.S., and analysts project peak sales could exceed $1 billion.
GSK previously marketed a Lyme vaccine called LYMErix but withdrew it from the market in 2002 due to poor sales and concerns about side effects. However, the disease has become more prevalent and widespread since then, potentially creating a more receptive market today, particularly among outdoor recreationists and residents of endemic areas in the Northeast and Upper Midwest of the U.S.
The VLA15 vaccine targets six prevalent serotypes of the Borrelia burgdorferi bacteria's outer surface protein A (OspA), providing coverage for both North American and European strains of the disease. The candidate has received Fast Track designation from the FDA, which could expedite its review process once the companies submit their applications.
Valneva, a smaller biotechnology company that would receive milestone payments and royalties on sales, saw its shares decline more sharply than Pfizer's following the announcement, reflecting the greater importance of the program to its overall business. H.C. Wainwright analysts maintained a Buy rating on Valneva, citing the positive immunogenicity and safety data.
For Pfizer, with a market capitalization of $153 billion, the Lyme vaccine represents a relatively small but strategically important addition to its vaccine portfolio, which has been seeking new growth drivers following the COVID-19 pandemic. The company's analyst target price stands at $28.54, modestly above Monday's trading price of $26.73, reflecting cautious optimism about its pipeline and commercial execution.
Pfizer's decision to pursue regulatory approval despite missing the primary endpoint underscores the company's confidence that the FDA will take a flexible approach given the strong efficacy signal and the significant public health need. The regulatory outcome will be closely watched by investors and the biotechnology industry as a test case for how agencies interpret clinical trial data when endpoint misses are driven by external factors like disease incidence rather than lack of biological effect.
If approved, the vaccine could potentially launch by late 2027, giving Pfizer a first-mover advantage in a market with no existing competition. The company has not disclosed its plans for pricing or commercialization strategy, but analysts will be watching for details on how Pfizer plans to position the vaccine—whether as a broad public health recommendation for at-risk populations or a more targeted offering for frequent outdoor enthusiasts.
The mixed Phase 3 results represent a classic pharmaceutical development scenario: strong clinical efficacy complicated by statistical design challenges. For investors, the key question becomes whether regulators will look past the formal endpoint miss and focus on the demonstrated 74% protection rate, or whether the companies will need to conduct additional studies to satisfy FDA requirements.